Experts Weigh Vitiligo's Cosmetic Label as Oral Therapies Near

Vitiligo carries a heavy psychological burden and, since 2022, an FDA-approved targeted therapy. Yet clinicians and payers who gathered at a New York roundtable described a familiar fight: insurers that still classify the disease as cosmetic, even as a wave of oral Janus kinase (JAK) inhibitors—priced far above the existing topical standard—prepares to enter the market.

The conversation took place in New York City on July 14, 2026, at an American Journal of Managed Care^® Population Health Roundtable^® titled "Advancing Value-Based Vitiligo Care." The discussion was moderated by Andrew Alexis, MD, MPH, professor of clinical dermatology at Weill Cornell Medicine. The room brought together board-certified dermatologists from academic and private practice settings, physician assistants and nurse practitioners, a biologic coordinator, and 2 payer representatives, giving the session what Alexis called "the whole 360°” view of the vitiligo patient journey.

A Diagnosis Delayed by Discouragement

Several participants said the patient journey begins with years of missed or dismissed diagnoses. "The real beginning of a patient journey in vitiligo is that they don't get diagnosed for a few years," said Nanette Silverberg, MD, MPHc, chief of pediatric dermatology at Mount Sinai. She said studies show patients typically see 3 to 4 practitioners before a proper diagnosis, often arriving with more extensive body surface area (BSA) involvement than if treated earlier, particularly on the hands, a site tied to long-term relapse risk.

Prince Adotama, MD, FAAD, assistant professor at NYU Grossman School of Medicine, said some patients are diagnosed correctly but discouraged from treatment: "They're seeing the wrong doctor who discourages them from actually pursuing treatment, says there are no options available to you. And so they go years; the disease has now progressed, and now they're seeing me." The psychological toll, panelists said, can rival the physical one. Silverberg said nearly all adolescents with vitiligo show altered quality-of-life scores by age 17 or 18,¹ and Adotama recounted a 21-year-old patient with genital vitiligo who was "very scared to engage in sexual relations" for fear others would assume he had a sexually transmitted infection.

Asked about the field's greatest unmet need, Adotama answered in a single word: "Insurance." Silverberg said no therapeutic ladder exists across insurers for vitiligo, which she said affects just over 2% of teenagers. "There is no structure" for consistent coverage, she said, leaving patients without a clear path to treatment.

Ruxolitinib Becomes First-Line, but Access Lags

Clinicians were largely unified that topical ruxolitinib, the first FDA-approved repigmentation therapy for vitiligo, has become their default first-line agent ahead of the off-label topical corticosteroids and calcineurin inhibitors used for decades. "It's first-line for head and neck. It's first-line for the body,” Silverberg said. "Why would I necessarily step through? I'll do shared decision-making with people. We'll look at what they can get on their insurance, but it's an FDA-approved product for first-line care."

Jeffrey Weinberg, MD, a dermatologist and founder of Infinity Dermatology, recalled how insurers greeted dupilumab when it reached the atopic dermatitis market: "Use methotrexate first. I'm going to use an inferior toxic drug that is not approved for AD, as opposed to one that is safe, effective, and approved. Sounds like a good choice." Amy Spizuoco, DO, FAOCD, owner of True Dermatology, added, "Sounds like cost might be getting in the way."

Alexis presented phase 3 data showing roughly 30% of patients on topical ruxolitinib achieved 75% or greater improvement in facial severity at week 24. Oral upadacitinib, tested in a more severe population, showed roughly 19% to 25% of patients meeting a co-primary endpoint of 75% facial improvement plus 50% total-body improvement at week 48.

Silverberg pressed the room: "Why do we know what the cost of ruxolitinib topically is [but] we don't know what the cost of [oral ruxolitinib] is?" Weinberg put the oral's list price near $85,000 annually, a figure Silverberg echoed, adding that it came with no rebate factored in. Jason Fehr, an independent actuarial consultant and former senior director of pharmacy advisory services at Optum, placed the net figure closer to $84,000, cautioning that manufacturer rebates—not reflected in that number—were likely "fairly aggressive."

Adotama argued against requiring formal severity scoring in practice: "VASI is very difficult for physicians to use in the office. And I think if we require it, it will be a barrier to people receiving any therapy at all." Panelists instead pointed to BSA estimates, before-and-after photography, and patient-reported outcomes, with Silverberg favoring target-area goals such as head and neck repigmentation, which patients rate as more psychologically significant than body disease.

Cosmetic Denials Collide With Clinical Consensus

Despite unanimous agreement among clinicians that vitiligo is a chronic autoimmune condition, panelists said payers routinely frame it otherwise. "You will get on the phone for a peer-to-peer, and they'll say...our plan considers this a cosmetic problem," Weinberg said. "I said, if you had it, I don't think you'd consider it cosmetic." Adotama said New York Medicaid has denied ruxolitinib coverage on cosmetic grounds despite advocacy letters from dermatology societies; Weinberg reframed the issue by saying, "They don't really consider it cosmetic; they just don't want to pay for it."

Mona Chitre, PharmD, senior vice president and chief pharmacy officer at Excellus BlueCross BlueShield, said pharmacy and therapeutics committees are frequently external and not staffed specifically for a condition as narrow as vitiligo. "There is this conversation that is constantly being had vs taxpayer dollars, premium dollars, and affordability," she said. Chitre said compendia such as UpToDate and OpenEvidence function as de facto guidelines absent formal step-therapy recommendations from dermatology societies; Silverberg said a 2024 JAMA Dermatology consensus guideline she coauthored does not recommend step therapy, and she was unaware of any US guideline that does.²

The Math Behind an $85,000 Pill

Fehr offered the most detailed accounting of how a plan would weigh an oral JAK inhibitor against topical ruxolitinib: "Three tubes of Opzelura in a year for roughly $6000—I can get a year's worth of Opzelura for 1 dose of oral JAK," he said, adding that even a 50% rebate would not close the gap. "I still don't get there on net cost." That math, combined with ruxolitinib's faster time to visible improvement, will likely keep plans favoring it in policy, particularly below 10% BSA involvement, he said.

Silverberg pushed back on a short-term framing of cost, arguing that undertreated vitiligo carries its own downstream expense: continued phototherapy, polypharmacy, and emerging evidence of cardiovascular and thyroid comorbidities. "If you don't effectively institute topical therapy to start with, you have patients who stay within the system under treatment forever," she said. Chitre acknowledged the tension but said plans remain constrained by sticker price regardless: "I think we can't get around an $85,000-per-year product on the market. It just is what it is." Fehr added that more treatment options cut both ways for payers: expanded choice can lower net cost through negotiation but also drives more patients toward treatment, raising volume against a fixed budget.

Attestation, Not Photos, Becomes the Utilization Management Standard

Administrative friction dominated much of the discussion's final stretch. Clinicians described prior authorization denials, step-therapy requirements, and patients who abandon treatment rather than navigate appeals. Erica Rendon, a biologic coordinator at True Dermatology, said electronic platforms have shortened turnaround substantially: "It has cut down so much time. In some occasions, especially if it's commercial, you can find out directly within a few minutes."

Asked what documentation would most influence a coverage decision, Fehr said payers are moving away from clinical photography toward simple attestation—an electronic check-box confirming a patient tried and failed a prior therapy—which he called "probably the easiest level of utilization management." Silverberg said the shift was clarifying, since her practice could focus documentation on BSA and treatment duration rather than photographic evidence.

Adotama said stigma around JAK inhibitors, reinforced by pharmacist counseling on boxed warnings, can undo careful patient education: "I get a message later on saying, on second thought, are you trying to harm me?" Claudia Slutzky, PA-C, a physician assistant at True Dermatology, said she has grown more comfortable discussing boxed-warning data with patients as a newer clinician trained alongside ruxolitinib's approval, and that comfort needs to extend to hesitant community dermatologists. Kerrin Cropano, NP, a nurse practitioner at Infinity Dermatology, said she does not file her own prior authorizations and would benefit from more direct feedback from insurers on what documentation they actually require.

Looking Ahead 6 to 18 Months

Asked what they would bring back to their organizations, several panelists converged on documentation discipline. Silverberg said she would ensure her charts systematically capture treatment failures, duration, and BSA metrics while continuing to contribute to forthcoming adult vitiligo guidelines. Adotama said he would incorporate patient-reported outcomes and BSA measures more consistently into his notes. Slutzky proposed that dermatology trainees help push for stronger society guidelines, noting the American Academy of Dermatology's last vitiligo-focused guidance predates 1987, according to Silverberg. Cropano and Rendon said clearer feedback from insurers on documentation requirements would streamline their work.

Weinberg was blunter: "I certainly would like to see drug costs go down." Spizuoco said she hoped to better explain drug pricing to patients, since most blame their physicians rather than the insurance system when a prescription is denied.

Fehr said the discussion reinforced rather than changed his entering assumption: vitiligo is not a large budget risk relative to its clinical and psychological stakes, and utilization management could be relaxed without meaningfully threatening plan finances. But he cautioned that once oral JAK inhibitors reach the market, plans will likely require patients to fail topical ruxolitinib first, at least below 10% BSA. "I would advocate, frankly, when oral comes, that there is absolutely a step... to go with an Opzelura before the oral just from a net cost perspective," he said. "Because once you let that horse out of the barn, you're not going to get it back."

Reference

1. Grimes P, Hamzavi IH, Bibeau K, et al. Mental health and psychosocial burden among patients with skin of color living with vitiligo: findings from the global VALIANT study. Dermatol Ther (Heidelb). 2025;15(7):1931-1939. doi:10.1007/s13555-025-01412-3

2. Renert-Yuval Y, Ezzedine K, Grimes P, et al. Expert recommendations on use of topical therapeutics for vitiligo in pediatric, adolescent, and young adult patients. JAMA Dermatol. 2024;160(4):453-461. doi:10.1001/jamadermatol.2024.0021